Skip to content

Effects of Self-monitoring on Outcome of Chronic Kidney Disease

Effects of Self-monitoring on Outcome of Chronic Kidney Disease - ESMO

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON38345
Enrollment
150
Registered
2010-06-24
Start date
2010-12-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease (CKD) Kidney Disease

Interventions

The intervention group receives (besides the care as usual) a self-management care model consisting of
self-monitoring sodium intake, keeping dietary diaries, receiving feedback, two motivational interviews and, if necessary, tailored self-management modules

Sponsors

Leids Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Informed Consent - Treated by an internist - Age above 18 years - Chronic kidney disease with a creatinin clearance of 20 ml/min/1.73m2 or above - a recent blood pressure higher than 135/85 mmHg or use of antihypertensive medication (at least 1 RAAS inhibitor) - Proteinuria above 0,2 g/L or above 0,3 g/24 u - Last 2 urine sodium measurements higher than 120 mmol/24 uur - Speaking fluently Dutch

Exclusion criteria

Exclusion criteria: - Blood pressure above 180/100 mmHg or below 125/75 mmHg - Diabetes Mellitus Type I patients - Renal transplant less than one year ago - Acute renal failure - Rapidly decrease of kidney function (decrease more than 6ml/min/1.73m2 in last year) - A myocard infarction or cerebrovasculair accident less then 6 months ago - Malignancy less than five years before inclusion (other than basocellular or squamous cell carcinoma of the skin) - Participating in other clinical trials requiring the use of study medication

Design outcomes

Primary

MeasureTime frame
Changes in sodium intake and changes in blood pressure.

Secondary

MeasureTime frame
Renal function (creatinine clearance), proteinuria, albuminuria, urinemarkers for tubulo-interstiele damage (KIM-1, NGAL en UMOD), antihypertensive medication and psychological outcome measures.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)